Ignite Creation Date:
2024-05-05 @ 5:26 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00456859
Status:
COMPLETED
Last Update Posted:
2007-10-18
First Post:
2007-04-04
Brief Title:
Carbonaceous Oral Adsorbents Effects on Progression of Chronic Kidney Disease
Sponsor:
Institute for Health Outcomes and Process Evaluation Reseach
Organization:
Institute for Health Outcomes and Process Evaluation Reseach
Study Overview
Official Title:
Carbonaceous Oral Adsorbents Effects on Progression of Chronic Kidney Disease CAP-KD
Status:
COMPLETED
Status Verified Date:
2007-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CAP-KD
Brief Summary:
The CAP-KD trial is a prospective multicenter randomized open-label two-arm parallel group comparison clinical trial and will be conducted as a researcher-directed study to assess the efficacy of Kremezin in preventing the progression of CKD We compare two groups of patients those receiving conventional treatment alone and those receiving such treatment paired with Kremezin
Detailed Description:
A clinical trial to evaluate the efficacy of the oral carbonaceous adsorbent Kremezin in preventing the progression of chronic kidney disease the Carbonaceous Oral Adsorbents Effects on Progression of Chronic Kidney Disease CAP-KD trial in predialysis patients In the trial we are comparing two treatments conventional treatment comprising an ACEI andor ARB together with a low-protein diet and combination treatment comprising the conventional treatment paired with Kremezin Furthermore we will compare the QOL in both groups of patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None